Inherited BRCA2 mutations predispose individuals to breast cancer and increase risk at other sites. Recent studies have suggested a role for the APC I1307K allele as a low-penetrance breast cancer susceptibility gene that enhances the phenotypic effects of BRCA1 and BRCA2 mutations. To model the consequences of inheriting mutant alleles of the BRCA2 and APC tumor suppressor genes, we examined tumor outcome in C57BL/6 mice with mutations in the Brca2 and Apc genes. We hypothesized that if the Brca2 and Apc genes were interacting to influence mammary tumor susceptibility, then mammary tumor incidence and/or multiplicity would be altered in mice that had inherited mutations in both genes. Female and male offspring treated with a single IP injection of 50 mg/kg N-ethyl-N-nitrosourea (ENU) at 35 days of age developed mammary adenoacanthomas by 100 days of age. The female Apc-mutant and Brca2/Apc double-mutant progeny had mean mammary tumor multiplicities of 6.7 ± 2.8 and 7.2 ± 2.7, respectively, compared to wild-type and Brca2-mutant females, which had mean mammary tumor multiplicities of 0.1 ±0.4 and 0.3 ± 0.5, respectively. Female ENU-treated Apc-mutant and Brca2/Apc double heterozygotes were also susceptible to premature ovarian failure. Thus, the inheritance of an Apc mutation predisposes ENU-treated female and male mice to mammary tumors and, in the case of female mice, to ovarian failure. These results indicate that mammary tumor development in Apc-mutant mice can progress independently of ovarian hormones. The Apc mutation-driven phenotypes were not modified by mutation of Brca2, perhaps because Brca2 acts in a hormonally dependent pathway of mammary carcinogenesis.
Bànkfalvi À. , Terpe H-J., Breukelmann D., Bier B., Rempe D., Pschadka G., Krech R., Lellè R-J., Boecker W. (1999). Immunophenotypic and prognostic analysis of E-cadherin and β-catenin expression during breast carcinogenesis and tumour progression: A comparative study with CD44. Histopathology34: 25—34.
2.
Bannerjee MR , Wood BG, Lin FK, Crump LR (1976). Organ culture of the whole mammary gland of the mouse. Tissue Cult Assoc Manual2: 457—461.
3.
Bennett LM, McAllister KA, Blackshear PE, Malphurs J., Goulding G., Collins NK, Ward T., Bunch DO, Eddy EM, Davis BJ, Wiseman RW (2000). Brca2-null embryonic survival is prolonged on the BALB/c genetic background. Mol Carcinog28: 174—183.
4.
Bièche I., Laurendeau I., Tozlu S., Olivi M., Vidaud D., Lidereau R., Vidaud M. (1999). Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. Cancer Res59: 2759—2765.
5.
Bièche I., Linderau R. (1995). Genetic alterations in breast cancer. Genes Chromosomes Cancer14: 227—251.
6.
Cadigan KM, Nusse R. (1997). Wnt signalling: A common theme in animal development . Genes Dev11: 3286—3305.
7.
Chan EF, Gat U., McNiff JM, Fuchs E. (1999). A common human skin tumour is caused by activating mutations in β-catenin. Nat Genet21: 410 — 413.
8.
Charpin C., Bonnier P., Garcia S., Andrac L., Crebassa B., Dorel M., Lavaut MN, Allasia C. (1999). E-cadherin and β-catenin expression in breast medullary carcinomas. Int J Oncol15: 258—292.
9.
Couch FJ, Farid LM, DeShano ML, et al (1996). BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet13: 123—125.
10.
de Leeuw WJF , Berx G., Vos CB, Peterse JL, van de Vijver MJ, Litvinov S., van Roy F., Cornelisse CJ, Cleton-Jansen AM (1997). Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol183: 404 — 411.
11.
Devilee P., Schuuring E., van de Vijver MJ, Cornelisse CJ (1994). Recent developments in the molecular genetic understanding of breast cancer. Crit Rev Oncog5: 247—270.
12.
Durrand M., Moles JP (1999). Beta-catenin mutations in a common skin cancer: Pilomatricoma. Bull Cancer86: 725—726.
13.
Gat U., DasGupta R., Degenstein L., Fuchs E. (1998). De novo hair follicle morphogenesis and hair tumors in mice expressing a truncated beta-catenin in skin. Cell95: 605—614.
14.
Groden J., Thliveris A., Samouwitz W., et al (1991). Identification and characterization of the familial adenomatous polyposis-coli gene. Cell66: 589—600.
15.
Hakem R., de la Pompa JL, and Mak TW (1998). Developmental Studies of Brca1 and Brca2 Knock-Out Mice. J Mamm Gland Biol Neoplasia,3, 431—445.
16.
He TC, Sparks AB, Rago C., Hermeking H., Zawel L., da Costa LT, Morin PJ, Vogelstein B., and Kinzler KW (1998). Identification of c-MYC as a target of the APC pathway. Science281, 509—512.
17.
Imagawa W., Yang J., Guzman R., Nandi S. (1994). Control of mammary gland development. In: The Physiology of Reproduction, 2nd ed. Knobil E, Neill JD (eds). Raven Press, New York, pp 1033— 1063.
18.
Johannsson O. , Loman N., Borg A., Olsson H. (1998). Pregnancy-associated breast cancer in BRCA1 and BRCA2 germline mutation carriers . Lancet352: 1359—1360.
19.
Kashiwaba M. , Tamura G., Ishida M. (1994). Abberations of the APC gene in primary breast carcinoma. J Cancer Res Clin Oncol120: 727—731.
20.
Korinek V., Barker N., Morin PJ, van Wichen D., de Wagner R., Kinsler KW, Vogelstein B., Clevers H. (1997). Constitutive transcriptional activation by a β-catenin-Tcf complex in APC-/- colon carcinoma. Science275: 1784—1787.
21.
Laken SJ, Petersen GM, Gruber SB, et al (1997). Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet17: 79—83.
22.
Ludwig T., Chapman DL, Papaiouannou VE, Efstratiadis A. (1997). Targeted mutations of breast cancer susceptibility gene homologs in mice: Lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/ p53 and Brca2/p53 nullizygous embryos. Genes Dev11: 1226— 1241.
23.
Marchant J. (1977). Animal models for tumors of the ovary and uterus . In: Animal Tumors of the Female Reproductive Tract: Spontaneous and Experimental, Cotchin E, Marchant J (eds). Springer-Verlag, New York, pp 1—65.
24.
Miller RJJr (1966). Simultaneous Statistical Inference . McGraw-Hill, New York, pp 90—94.
25.
Morin PJ, Sparks AB, Korinek V., Barker N., Clevers H., Vogelstein B., Kinzler KW (1997). Activation of β-catenin-Tcf signalling in colon cancer by mutations in β-catenin or APC. Science275: 1787— 1790.
26.
Moser AR, Luongo C., Gould KA, McNeley MK, Shoemaker AR, Dove WF ( 1995). ApcMin: A mouse model for intestinal and mammary tumorigenesis. Eur J Cancer31A: 1061—1064.
27.
Moser AR, Mattes EM, Dove WF, Lindstrom MJ, Haag JD, Gould MN (1993). Apc Min, a mutation in the murine Apc gene, predisposes to mammary carcinomas and focal alveolar hyperplasias. Proc Natl Acad Sci USA90: 8977—8981.
28.
Murphy ED, Beamer WG (1973). Plasma gonadotropin levels during early tumorigenesis mice of the Wx/Wv genotype. Cancer Res33: 721—723.
29.
Nishisho I. , Nakamura Y., Misyoshi Y., et al (1991). Mutations of chromosome 5q21 genes in FAP and colorectal-cancer patients. Science253: 665—669.
30.
Papkoff J., Aikawa M. (1998). WNT-1 and HGF regulate GSK2β activity and β-catenin signaling in mammary epithelial cells. Biochem Biophys Res Comm247: 851—858.
31.
Pelengaris S., Littlewood T., Khan M., Elia G., Evan G. (1999). Reversible activation of c-Myc in skin: Induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell3: 565— 577.
32.
Rahman N., Stratton M. (1998). The genetics of breast cancer susceptibility. Annu Rev Genet32: 95—120.
33.
Redston M., Nathanson KL, Yuan ZQ, et al (1998). The APC I1307K allele and breast cancer risk. Nat Genet20: 13—14.
34.
Roose J., Huls G., van Beest M., Moerer P., van der Horn K., Goldschmeding R., Logtenberg T., Clever H. (1999). Synergy between tumor suppressor APC and the β-catenin-T cf 4 target Tcf1. Science285: 1923—1926.
35.
Saitoh A., Hansen LA, Vogel JC, Udey MC ( 1998). Characterization of Wnt gene expression in murine skin: Possible involvement of epidermins-derived Wnt-4 in cutaneous epithelial-mesenchymal interactions. Exp Cell Res243: 150—160.
36.
Seely JC, Boorman GA (1999). Mammary gland and specialized sebaceous glands . In: Pathology of the Mouse, Maronpot RR (ed. Cache River Press, Vienna, Illinois, pp 613—635.
37.
Sharan SK, Morimatsu M., Albrecht U., Lim DS, Regel E., Dinh C., Sands A., Eichele G., Hasty P., Bradley A. (1997). Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature386: 804 — 810.
38.
Shibata H., Toyama K., Shioya H., et al (1997). Rapid colorectal adenoma formation initiated by conditional targeting of the APC gene. Science278: 120—123.
39.
Siegel S. (1956). Nonparametric Statistics for the Behavioral Sciences . McGraw-Hill, New York.
40.
Suzuki A., de la Pompa JL, Hakem R., et al (1997). Brca2 is required for embryonic cellular proliferation in the mouse. Genes Dev11: 1242—1252.
41.
The Breast Cancer Linkage Consortium (1999). Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst91: 1310—1316.
42.
Ursin G., Henderson BE, Haile RW, Pike MC, Zhou N., Diep A., Bernstein L. (1997). Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women?Cancer Res57: 3678—3681.
43.
Van der Houven van Oordt CW, Smits R., Williamson SLH, Luz A., Khan PM, Fodde R., van der Eb AJ, Breuer ML (1997). Intestinal and extra-intestinal tumor multiplicities in the Apc1638N mouse model after exposure to x-rays . Carcinogenesis18: 2197—2203.
44.
Van der Houven van Oordt C., Smits R., Schouten TG, Houwing-Duistermaat JJ, Williamson SLH, Luz A., Khan PM, van der Eb AJ, Breuer ML, Fodde R. (1999). The genetic background modifies the spontaneous and X-ray-induced tumor spectrum in the Apc1638N mouse model. Genes Chromosomes Cancer24: 191— 198.
45.
Woodage T., King SM, Wacholder S., Hartge P., Struewing JP, McAdams M., Laken SJ, Tucker MA, Brody LC (1998). The APC I1307K allele and cancer risk in a community-based study of Ashkenazi Jews. Nat Genet20: 62—65.
46.
Yang Y., Spitzer E., Meyer D., Sachs M., Niemann C., Hartmann G., Weidner KM, Birchmeier C., Birchmeier W. (1995). Sequential requirement of hepatocyte growth factor and neuregulin in the morphogenesis and differentiation of the mammary gland . J Cell Biol131: 215—226.
